Exciting Upcoming Investor Conferences for Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is preparing to showcase its innovations and developments in the life sciences industry at several upcoming investor conferences. These events are an excellent opportunity for stakeholders to gain insights into the company’s advancements and contributions to research and diagnostics.
Details of the Conferences
Wells Fargo Healthcare Conference
The first conference Bio-Techne will attend is the Wells Fargo Healthcare Conference on September 3, 2025. This significant event will take place at 10:15 AM EDT, where the company plans to share its recent progress and future outlook.
Baird Global Healthcare Conference
Following that, Bio-Techne is set to present at the Baird 2025 Global Healthcare Conference on September 9, 2025, at 9:05 AM EDT. Here, the company will detail its innovative tools and reagents that are pivotal in the life sciences sector.
Morgan Stanley Global Healthcare Conference
On September 10, 2025, Bio-Techne will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference, scheduled for 10:45 AM EDT. This event serves as a platform for the company to engage with investors over its strategic initiatives and market presence.
Access to Presentations
For those interested in following Bio-Techne’s presentations live, a webcast will be available through the company’s Investor Relations website. This is a chance for investors and analysts to see firsthand the insights shared during these key presentations, highlighting the company’s direction in the competitive landscape of life sciences.
About Bio-Techne Corporation
Bio-Techne Corporation stands as a leader in providing innovative solutions to the life sciences community. The company develops and supplies bioactive reagents and tools aimed at facilitating research and accurate diagnostics. With a diverse portfolio boasting over 100,000 products, Bio-Techne has generated substantial revenue exceeding $1.2 billion in net sales during fiscal 2025. With a workforce of around 3,100 employees spread across the globe, Bio-Techne is committed to enhancing scientific inquiries and aiding in the drug discovery process.
By focusing on the biological processes associated with diseases, Bio-Techne is vital in the fight against various health challenges. Their products not only empower researchers but also enhance the accuracy of clinical tests, contributing significantly to advancements in healthcare. The expansive product offerings and ongoing dedication to innovation reinforce Bio-Techne’s commitment to supporting scientific progress.
Contact Information
For more information regarding Bio-Techne and its operations, you can reach out to David Clair, Vice President of Investor Relations & Corporate Development. His insight is invaluable for understanding the company’s strategies and initiatives.
Frequently Asked Questions
What conferences is Bio-Techne presenting at?
Bio-Techne is presenting at the Wells Fargo Healthcare Conference, Baird Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference.
Where can I access the presentations?
You can access the live webcasts of the presentations on Bio-Techne's Investor Relations website.
What does Bio-Techne specialize in?
Bio-Techne specializes in providing innovative tools and bioactive reagents to the life sciences sector, supporting both research and clinical diagnostics.
How large is Bio-Techne's product portfolio?
Bio-Techne has an impressive product portfolio comprising over 100,000 items, catering to various facets of scientific research.
What are Bio-Techne's financial achievements?
In the fiscal year 2025, Bio-Techne reported net sales exceeding $1.2 billion, showcasing its strong market presence and impact in the life sciences industry.